Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2024-05-16 Legal Proceedings Report
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
소송등의제기ㆍ신청(일정금액이상의청구)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure regarding a lawsuit ('소송등의제기ㆍ신청') filed against the company (파멥신). It details the nature of the claim, the amount involved, the court, and the company's planned response. This fits the definition of a Legal Proceedings Report (LTR) as it concerns significant legal matters involving the company.
2024-05-16 Korean
투자판단관련주요경영사항(임상시험계획자진취하등) (전이성 삼중음성 유방암 환자에서 펨브롤리주맙(Pembrolizumab)과 병용한 올린베시맙(Olinvacimab)의 제2상, 공개, 다기관 임상시험)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from a Korean company (PharmAbcine) regarding the voluntary withdrawal of a clinical trial (Phase II study of Olinvacimab). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since this is a specific regulatory announcement regarding clinical trial status and does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2024-04-29 Korean
기타시장안내 (기업심사위원회 심의속개 결정 안내)
Legal Proceedings Report Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange regarding the status of PharmAbcine's listing eligibility review (corporate review committee decision). It does not contain financial statements, proxy materials, or other specific report types, but rather serves as a formal regulatory announcement regarding a company's listing status. As it does not fit into specific categories like delisting or M&A, it falls under the general regulatory filing category.
2024-04-25 Korean
기타시장안내 (개선계획서 제출)
Legal Proceedings Report Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange regarding the submission of an improvement plan by the company 'PharmAbcine' following a listing eligibility review. It does not contain financial statements or management reports, but rather serves as a formal regulatory update on the company's listing status. As it is a regulatory announcement that does not fit into specific categories like M&A or dividends, it falls under the RNS (Regulatory Filings) category.
2024-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과). It details the approval of financial statements, dividend decisions, appointment of directors/auditors, and the outcome of specific agenda items. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2024-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the resignation of an outside director (사외이사). It details the change in board composition, specifically the resignation of a director and his subsequent appointment as an auditor. This falls under the category of board/management changes.
2024-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.